Top

Published in:

01-06-2015 | Intravascular Imaging (I.-K. Jang, Section Editor)

Vulnerable Plaque: Molecular Imaging

Authors: Sunki Lee, Jin Won Kim

Published in: Current Cardiovascular Imaging Reports | Issue 6/2015

Abstract

Despite the remarkable advances in cardiovascular imaging over the last decade, it is still challenging to identify high-risk atherosclerotic plaques prior to onset of major cardiovascular complications. Accumulating knowledge regarding the pathophysiological properties of vulnerable plaque (VP) has driven the development of molecular imaging technologies that target biologic process to characterize vulnerable plaques. Given the importance of VP detection in vivo, molecular imaging has emerged as an attractive diagnostic tool to more accurately estimate the risk of plaque rupture.

Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Executive summary: heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation. 2013;127(1):143–52. doi:10.1161/CIR.0b013e318282ab8f.CrossRefPubMed

Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–95. doi:10.1056/NEJMra043430.CrossRefPubMed

Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473(7347):317–25.CrossRefPubMed

Sanz J, Fayad ZA. Imaging of atherosclerotic cardiovascular disease. Nature. 2008;451(7181):953–7. doi:10.1038/nature06803.CrossRefPubMed

Kusters DH, Tegtmeier J, Schurgers LJ, Reutelingsperger CP. Molecular imaging to identify the vulnerable plaque—from basic research to clinical practice. Mol Imaging Biol. 2012;14(5):523–33. doi:10.1007/s11307-012-0586-7.CrossRefPubMed

Silvestre-Roig C, de Winther MP, Weber C, Daemen MJ, Lutgens E, Soehnlein O. Atherosclerotic plaque destabilization: mechanisms, models, and therapeutic strategies. Circ Res. 2014;114(1):214–26. doi:10.1161/CIRCRESAHA.114.302355.CrossRefPubMed

Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation. 2003;108(14):1664–72. doi:10.1161/01.cir.0000087480.94275.97.CrossRefPubMed

Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. The New England journal of medicine. 2013;368(21):2004–13. doi:10.1056/NEJMra1216063

Narula J, Nakano M, Virmani R, Kolodgie FD, Petersen R, Newcomb R, et al. Histopathologic characteristics of atherosclerotic coronary disease and implications of the findings for the invasive and noninvasive detection of vulnerable plaques. J Am Coll Cardiol. 2013;61(10):1041–51. doi:10.1016/j.jacc.2012.10.054.CrossRefPubMedCentralPubMed

10.

Derksen WJ, Peeters W, van Lammeren GW, Tersteeg C, de Vries JP, de Kleijn DP, et al. Different stages of intraplaque hemorrhage are associated with different plaque phenotypes: a large histopathological study in 794 carotid and 276 femoral endarterectomy specimens. Atherosclerosis. 2011;218(2):369–77. doi:10.1016/j.atherosclerosis.2011.07.104.CrossRefPubMed

11.

Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320(14):915–24. doi:10.1056/nejm198904063201407.CrossRefPubMed

12.

Kaufmann BA, Sanders JM, Davis C, Xie A, Aldred P, Sarembock IJ, et al. Molecular imaging of inflammation in atherosclerosis with targeted ultrasound detection of vascular cell adhesion molecule-1. Circulation. 2007;116(3):276–84. doi:10.1161/CIRCULATIONAHA.106.684738.CrossRefPubMed

13.

Nahrendorf M, Keliher E, Panizzi P, Zhang H, Hembrador S, Figueiredo JL, et al. 18 F-4V for PET-CT imaging of VCAM-1 expression in atherosclerosis. J Am Coll Cardiol Img. 2009;2(10):1213–22. doi:10.1016/j.jcmg.2009.04.016.

14.

McAteer MA, Schneider JE, Ali ZA, Warrick N, Bursill CA, von Zur Muhlen C, et al. Magnetic resonance imaging of endothelial adhesion molecules in mouse atherosclerosis using dual-targeted microparticles of iron oxide. Arterioscler Thromb Vasc Biol. 2008;28(1):77–83. doi:10.1161/ATVBAHA.107.145466.CrossRefPubMedCentralPubMed

15.

Mulder WJ, Jaffer FA, Fayad ZA, Nahrendorf M. Imaging and nanomedicine in inflammatory atherosclerosis. Sci Transl Med. 2014;6(239):239sr1. doi:10.1126/scitranslmed.3005101.CrossRefPubMedCentralPubMed

16.

Tawakol A, Migrino RQ, Bashian GG, Bedri S, Vermylen D, Cury RC, et al. In vivo 18 F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol. 2006;48(9):1818–24. doi:10.1016/j.jacc.2006.05.076.

17.•

Tawakol A, Fayad ZA, Mogg R, Alon A, Klimas MT, Dansky H, et al. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study. J Am Coll Cardiol. 2013;62(10):909–17. doi:10.1016/j.jacc.2013.04.066. This article demonstrates the feasibility of therapeutic monitoring for individual patients by using a noninvasive PET/CT imaging with FDG probe.CrossRefPubMed

18.

Rogers IS, Nasir K, Figueroa AL, Cury RC, Hoffmann U, Vermylen DA, et al. Feasibility of FDG imaging of the coronary arteries: comparison between acute coronary syndrome and stable angina. J Am Coll Cardiol Img. 2010;3(4):388–97. doi:10.1016/j.jcmg.2010.01.004.CrossRef

19.

Kooi ME, Cappendijk VC, Cleutjens KB, Kessels AG, Kitslaar PJ, Borgers M, et al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation. 2003;107(19):2453–8. doi:10.1161/01.cir.0000068315.98705.cc.CrossRefPubMed

20.

Tang TY, Howarth SP, Miller SR, Graves MJ, Patterson AJ, UK-I JM, et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease. J Am Coll Cardiol. 2009;53(22):2039–50. doi:10.1016/j.jacc.2009.03.018.CrossRefPubMed

21.

Morishige K, Kacher DF, Libby P, Josephson L, Ganz P, Weissleder R, et al. High-resolution magnetic resonance imaging enhanced with superparamagnetic nanoparticles measures macrophage burden in atherosclerosis. Circulation. 2010;122(17):1707–15. doi:10.1161/CIRCULATIONAHA.109.891804.CrossRefPubMedCentralPubMed

22.

Lancelot E, Amirbekian V, Brigger I, Raynaud JS, Ballet S, David C, et al. Evaluation of matrix metalloproteinases in atherosclerosis using a novel noninvasive imaging approach. Arterioscler Thromb Vasc Biol. 2008;28(3):425–32. doi:10.1161/ATVBAHA.107.149666.CrossRefPubMed

23.

Hyafil F, Vucic E, Cornily JC, Sharma R, Amirbekian V, Blackwell F, et al. Monitoring of arterial wall remodelling in atherosclerotic rabbits with a magnetic resonance imaging contrast agent binding to matrix metalloproteinases. Eur Heart J. 2011;32(12):1561–71. doi:10.1093/eurheartj/ehq413.CrossRefPubMedCentralPubMed

24.

Deguchi JO, Aikawa M, Tung CH, Aikawa E, Kim DE, Ntziachristos V, et al. Inflammation in atherosclerosis: visualizing matrix metalloproteinase action in macrophages in vivo. Circulation. 2006;114(1):55–62. doi:10.1161/CIRCULATIONAHA.106.619056.CrossRefPubMed

25.

Razavian M, Tavakoli S, Zhang J, Nie L, Dobrucki LW, Sinusas AJ, et al. Atherosclerosis plaque heterogeneity and response to therapy detected by in vivo molecular imaging of matrix metalloproteinase activation. J Nucl Med. 2011;52(11):1795–802. doi:10.2967/jnumed.111.092379.CrossRefPubMedCentralPubMed

26.

Chen J, Tung CH, Allport JR, Chen S, Weissleder R, Huang PL. Near-infrared fluorescent imaging of matrix metalloproteinase activity after myocardial infarction. Circulation. 2005;111(14):1800–5. doi:10.1161/01.cir.0000160936.91849.9f.CrossRefPubMedCentralPubMed

27.

Jaffer FA, Kim DE, Quinti L, Tung CH, Aikawa E, Pande AN, et al. Optical visualization of cathepsin K activity in atherosclerosis with a novel, protease-activatable fluorescence sensor. Circulation. 2007;115(17):2292–8. doi:10.1161/circulationaha.106.660340.CrossRefPubMed

28.

Jaffer FA, Vinegoni C, John MC, Aikawa E, Gold HK, Finn AV, et al. Real-time catheter molecular sensing of inflammation in proteolytically active atherosclerosis. Circulation. 2008;118(18):1802–9. doi:10.1161/circulationaha.108.785881.CrossRefPubMedCentralPubMed

29.••

Yoo H, Kim JW, Shishkov M, Namati E, Morse T, Shubochkin R, et al. Intra-arterial catheter for simultaneous microstructural and molecular imaging in vivo. Nat Med. 2011;17(12):1680–4. doi:10.1038/nm.2555. This is the first study of catheter-based, dual-modality intravascular OFDI/NIRF imaging in vivo to identify high-risk plaques.CrossRefPubMedCentralPubMed

30.••

Lee S, Lee MW, Cho HS, Song JW, Nam HS, Oh DJ, et al. Fully integrated high-speed intravascular optical coherence tomography/near-infrared fluorescence structural/molecular imaging in vivo using a clinically available near-infrared fluorescence-emitting indocyanine green to detect inflamed lipid-rich atheromata in coronary-sized vessels. Circ Cardiovasc Interv. 2014;7(4):560–9. doi:10.1161/circinterventions.114.001498. This study demonstrates important progress in intravascular structural/molecular imaging of high-risk atheroma in coronary-sized vessels in vivo using a clinically available NIRF-emiiting ICG by utilizing an advanced OCT-NIRF system.CrossRefPubMed

31.

Werner SG, Langer HE, Schott P, Bahner M, Schwenke C, Lind-Albrecht G, et al. Indocyanine green-enhanced fluorescence optical imaging in patients with early and very early arthritis: a comparative study with magnetic resonance imaging. Arthritis Rheum. 2013;65(12):3036–44. doi:10.1002/art.38175.CrossRefPubMed

32.

Vinegoni C, Botnaru I, Aikawa E, Calfon MA, Iwamoto Y, Folco EJ, et al. Indocyanine green enables near-infrared fluorescence imaging of lipid-rich, inflamed atherosclerotic plaques. Sci Transl Med. 2011;3(84):84ra45. doi:10.1126/scitranslmed.3001577.CrossRefPubMedCentralPubMed

33.

Kim S, Lee MW, Cho HS, Song JW, Lee S, Oh DJ, et al. Abstract 17216: Intracoronary Dual-modal OCT/NIRF Structural-Molecular Imaging with a Clinical Dose of Indocyanine Green (ICG) for Detection of High-risk Coronary Plaques in Diabetic Swine Model. Circulation. 2014;130 Suppl 2:A17216.

34.

Tabas I. Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol. 2010;10(1):36–46. doi:10.1038/nri2675.PubMedCentralPubMed

35.

Wang JC, Bennett M. Aging and atherosclerosis: mechanisms, functional consequences, and potential therapeutics for cellular senescence. Circ Res. 2012;111(2):245–59. doi:10.1161/circresaha.111.261388.CrossRefPubMed

36.

Kietselaer BL, Reutelingsperger CP, Heidendal GA, Daemen MJ, Mess WH, Hofstra L, et al. Noninvasive detection of plaque instability with use of radiolabeled annexin A5 in patients with carotid-artery atherosclerosis. N Engl J Med. 2004;350(14):1472–3. doi:10.1056/nejm200404013501425.CrossRefPubMed

37.

Laufer EM, Winkens MH, Narula J, Hofstra L. Molecular imaging of macrophage cell death for the assessment of plaque vulnerability. Arterioscler Thromb Vasc Biol. 2009;29(7):1031–8. doi:10.1161/ATVBAHA.108.165522.CrossRefPubMed

38.

Ramstrom S, O’Neill S, Dunne E, Kenny D. Annexin V binding to platelets is agonist, time and temperature dependent. Platelets. 2010;21(4):289–96. doi:10.3109/09537101003660564.CrossRefPubMed

39.

Edgington LE, Berger AB, Blum G, Albrow VE, Paulick MG, Lineberry N, et al. Noninvasive optical imaging of apoptosis by caspase-targeted activity-based probes. Nat Med. 2009;15(8):967–73. doi:10.1038/nm.1938.CrossRefPubMedCentralPubMed

40.

Hight MR, Cheung YY, Nickels ML, Dawson ES, Zhao P, Saleh S, et al. A peptide-based positron emission tomography probe for in vivo detection of caspase activity in apoptotic cells. Clin Cancer Res. 2014;20(8):2126–35. doi:10.1158/1078-0432.CCR-13-2444.CrossRefPubMedCentralPubMed

41.

Virmani R, Kolodgie FD, Burke AP, Finn AV, Gold HK, Tulenko TN, et al. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol. 2005;25(10):2054–61. doi:10.1161/01.ATV.0000178991.71605.18.CrossRefPubMed

42.

Su H, Gorodny N, Gomez LF, Gangadharmath UB, Mu F, Chen G, et al. Atherosclerotic plaque uptake of a novel integrin tracer (1)(8)F-Flotegatide in a mouse model of atherosclerosis. J Nucl Cardiol. 2014;21(3):553–62. doi:10.1007/s12350-014-9879-3.CrossRefPubMedCentralPubMed

43.

Winter PM, Morawski AM, Caruthers SD, Fuhrhop RW, Zhang H, Williams TA, et al. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation. 2003;108(18):2270–4. doi:10.1161/01.cir.0000093185.16083.95.CrossRefPubMed

44.

Beer AJ, Pelisek J, Heider P, Saraste A, Reeps C, Metz S, et al. PET/CT imaging of integrin alphavbeta3 expression in human carotid atherosclerosis. J Am Coll Cardiol Img. 2014;7(2):178–87. doi:10.1016/j.jcmg.2013.12.003.CrossRef

45.

Otsuka F, Sakakura K, Yahagi K, Joner M, Virmani R. Has our understanding of calcification in human coronary atherosclerosis progressed? Arterioscler Thromb Vasc Biol. 2014;34(4):724–36. doi:10.1161/atvbaha.113.302642.CrossRefPubMedCentralPubMed

46.

Aikawa E, Nahrendorf M, Figueiredo JL, Swirski FK, Shtatland T, Kohler RH, et al. Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo. Circulation. 2007;116(24):2841–50. doi:10.1161/circulationaha.107.732867.CrossRefPubMed

47.

Dweck MR, Chow MW, Joshi NV, Williams MC, Jones C, Fletcher AM, et al. Coronary arterial 18 F-sodium fluoride uptake: a novel marker of plaque biology. J Am Coll Cardiol. 2012;59(17):1539–48. doi:10.1016/j.jacc.2011.12.037.

48.••

Joshi NV, Vesey AT, Williams MC, Shah ASV, Calvert PA, Craighead FHM, et al. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial. Lancet. 2014;383(9918):705–13. doi:10.1016/s0140-6736(13)61754-7. This is the first noninvasive molecular imaging method using 18F-NaF PET/CT for detecting high-risk plaques and localizing ruptured plaques as well.CrossRefPubMed

49.

Caplan JD, Waxman S, Nesto RW, Muller JE. Near-infrared spectroscopy for the detection of vulnerable coronary artery plaques. J Am Coll Cardiol. 2006;47(8 Suppl):C92–6. doi:10.1016/j.jacc.2005.12.045.CrossRefPubMed

50.

Jang IK. Near infrared spectroscopy: another toy or indispensible diagnostic tool? Circ Cardiovasc Interv. 2012;5(1):10–1. doi:10.1161/circinterventions.111.967935.CrossRefPubMed

51.

Madder RD, Goldstein JA, Madden SP, Puri R, Wolski K, Hendricks M, et al. Detection by near-infrared spectroscopy of large lipid core plaques at culprit sites in patients with acute ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2013;6(8):838–46. doi:10.1016/j.jcin.2013.04.012.CrossRefPubMed

52.•

Oemrawsingh RM, Cheng JM, Garcia-Garcia HM, van Geuns RJ, de Boer SP, Simsek C, et al. Near-infrared spectroscopy predicts cardiovascular outcome in patients with coronary artery disease. J Am Coll Cardiol. 2014;64(23):2510–8. doi:10.1016/j.jacc.2014.07.998. First prospective study assess the long-term prognostic value of intracoronary NIRS in coronary disease patients.CrossRefPubMed

53.

Ay I, Blasi F, Rietz TA, Rotile NJ, Kura S, Brownell AL, et al. In vivo molecular imaging of thrombosis and thrombolysis using a fibrin-binding positron emission tomographic probe. Circ Cardiovasc Imaging. 2014;7(4):697–705. doi:10.1161/circimaging.113.001806.CrossRefPubMed

Title: Vulnerable Plaque: Molecular Imaging
Authors: Sunki Lee
Jin Won Kim
Publication date: 01-06-2015
Publisher: Springer US
Published in: Current Cardiovascular Imaging Reports / Issue 6/2015
Print ISSN: 1941-9066
Electronic ISSN: 1941-9074
DOI: https://doi.org/10.1007/s12410-015-9338-9

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Vulnerable Plaque: Molecular Imaging

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2015

Strategy for Building a Successful Coronary CT Angiography Program in the Emergency Department

Management of Coronary Artery Calcium and Coronary CTA Findings

Cardiac Magnetic Resonance Imaging in Ventricular Remodelling

Advances in CMR of Post-ablation Atrial Injury

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page